PET/MRI (AXUMIN) STUDY OF MEN WITH HIGHLY SUSPICIOUS MRI LESIONS THAT SHOWED NO CLINICALLY SIGNIFICANT PROSTATE CANCER FOLLOWING MRI FUSION TARGETED BIOPSY

Brief description of study

The objective of this study is to find out if positron emission tomography (PET) imaging with 18-F fluciclovine (Axumin) identifies clinically significant prostate cancer in men like yourself who have a highly suspicious MRI lesion (PI-RADS score of 4 and 5 lesion) and the MRI-ultrasound fusion biopsy (MRFTB) does not show cancer.


Clinical Study Identifier: s18-00601
ClinicalTrials.gov Identifier: NCT03635866


If you are registered as a volunteer, please login to the dashboard to send referrals.